GSK aids hepatitis prevention and treatment in poverty-stricken areas of the western region

Today, on the occasion of World Hepatitis Day, under the guidance and support of the National Health and Family Planning Commission (NHFPC), GSK and the China Health Promotion Foundation (CHPF) signed a Letter of Intent. Under the framework of a strategic partnership, GSK will support CHPF to carry out the "Poverty Alleviation and Health Preservation - Hepatitis Prevention and Treatment" programme. This programme will be in line with the broader strategic aims of China's "Healthy Silk Road" initiative to strengthen academic exchanges and cooperation between the western region and the southeast coastal areas of China, improve the country's prevention and treatment of hepatitis, and enhance the hepatitis prevention system and team capacity building.

To address regional discrepancies in medical treatment standards across the country, the project plans to select hospitals from Beijing, Shanghai, and Guangzhou to collectively establish the China Hepatitis Prevention Training Institute. Aimed at supporting Western China, the Institute is expected to train local personnel who will form the backbone of hepatitis prevention and treatment network and drive improvements in the western region’s hepatitis treatment capability. The programme will also establish an expert medical team, which will visit poverty-stricken areas of the western region to carry out grassroots hepatitis prevention and control work, as well as health promotion activities. In addition, this programme will employ a variety of apparoches, including: live events, clinical consultations, health lectures, publicity displays, and media reporting, to further promote health education on the prevention and treatment of hepatitis in Western China.

Viral hepatitis is a major public health issue. In April this year, the World Health Organization (WHO) in Geneva published the “Global Hepatitis Report 2017,” which states that there are currently an estimated 325 million people infected with the hepatitis B or C virus. The WHO has listed viral hepatitis as one of the major threats to global public health. As such, the Chinese government attaches great importance to preventing and treating the disease. Following the gradual implementation of prevention and control strategies, China has achieved remarkable results in the prevention and control of viral hepatitis. However, issues still exist, such as the country’s vast size and discrepancies in regional development, large quantity of patients already infected, and espectially, the urgent need to improve clinical prevention and control solutions as well as the promotion of public health awareness in poverty-stricken areas.

Thomas Willemsen, General Manager, GSK China Pharmaceuticals and Vaccines, said, "Supporting the Chinese government’s strategic initiative of 'Healthy Silk Road' is our commitment to be 'in China, with China, for China'. Over the past 18 years, we’ve been providing Chinese physicians and patients with a holistic prevention and treatment solution ranging from vaccination to effective antiviral medicines. In recent years, we’ve been supporting grassroots physician training  programme on chronic hepatitis B prevention and treatment. Last year, we announced the establishement of a public health institute in Beijing dedicated to the research and development of infectious diseases including hepatitis B. Today’s collaboration signing will mark another milestone for our continous support of China’s prevention and control of viral hepatitis. We hope that through the implementation of this programme, the level of viral hepatitis prevention and control across Western China, especially in the poverty-stricken areas, will be improved, public health awareness can be strengthened, and the access to effective treatment solutions will be further enhanced.”

As part of the ‘in China, with China, for China’ strategy, GSK China has:

  • Announced Seroxat CR and Tykerb on the list of reimbursed drugs as results of the national health insurance negotiations in July 2017.
  • Announced a strategic partnership with academia to co-develop health big-data system and upgrade the management of respiratory diseases in June 2017.
  • Aided the National Preventive Vaccination Services and Management Training Programme, helmed by the Chinese Preventive Medicine Association under the guidance of the National Health and Family Planning Commission, with the support of the China Centre for Disease Control and Prevention that officially kicked off in June 2017.
  • Announced Viread, Arixtra, Requip and Mivacron included in the “2017 National Reimbursement Drug List” in Mar 2017.
  • Joined hands with the Home of Red Ribbon to combat HIV/AIDS, unveiling plan to support people living with HIV in Nov 2016.
  • Announced the strategic partnership with China Preventive Medicine Association (CPMA) to address major public health challenges in China in Nov 2016.
  • Announced the approval of Cervarix in China to help protect women from cervical cancer in July 2016.
  • Announced a Memorandum of Understanding between the GSK Institute for Infectious Diseases and Public Health and Tsinghua University to tackle global public health challenges in June 2016.
  • Launched Tivicay, an innovative HIV drug, in June 2016.
  • Participated in the national price negotiation pilot and announced a price reduction of our first line chronic hepatitis B treatment, Viread, by up to 67% in May 2016.
  • Announced a Beijing-based Institute for Infectious Disease and Public Health to conduct local development programmes for pivotal HIV and TB R&D assets in March 2016.
  • Partnered with the National Health and Family Planning Commission on a multi-year programme to fund independent training programmes in Hepatitis and COPD for over 13,000 healthcare professionals from September 2015.
  • Formalised a partnership with Shanghai-based Desano Pharmaceuticals to locally manufacture the Active Pharmaceutical Ingredient for Tivicay (dolutegravir) in July 2015.
  • Transformed our commercial operating model to actively contribute to improving the quality of scientific exchanges with healthcare professionals for the benefit of patients since May 2015.



GSK – one of the world’s leading research-based pharmaceutical and healthcare companies – is committed to improving the quality of human life by enabling people to do more, feel better and live longer.  For further information please visit


GSK commitment to China

We are a science-led global healthcare company. We research, develop and manufacture a wide range of medicines, vaccines and consumer healthcare products. People are at the heart of what we do. We strive to bring high quality, high performing products to everyone who needs them. Creating innovative products and improving access to them is critical to our mission, allowing us to help build stronger, healthier communities. In China, and around the world, we are on a mission to help people do more, feel better, live longer. We are in China, with China, for China, and our commitment remains unwavering.


GSK enquiries:

Susan Song        (China)


Cautionary statement regarding forward-looking statements
GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described under Item 3.D 'Principal risks and uncertainties' in the company's Annual Report on Form 20-F for 2016.